TransMedics Group Inc. (TMDX)
NASDAQ: TMDXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TMDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.96B
- P/E (TTM)
- 23.23
- Forward P/E
- 34.31
- EPS (TTM)
- $3.67
- Dividend yield
- None
- 52-week range
- 60.11 – 156.00
- Day range
- 83.89 – 91.62
- Volume / Avg
- 1.59M / 930.13K
- Beta
- —
- Shares outstanding
- 34.73M
52-week range
TMDX stock today
TransMedics Group (TMDX) closed at $85.25 on Nov 20, down 9.33% (-$8.77), versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $156.00, set on Dec 2, 2025 and 41.8% above the 52-week low of $60.11, in the middle of the past year's range. TMDX is down 29.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.9%.
At 23.2x trailing earnings, TransMedics Group trades above the peer-group median of 18.0x. Its forward P/E of 34.3x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About TransMedics Group
Company profileTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Dr. Waleed H. Hassanein M.D.
- Headquarters
- Andover, MA
- Employees
- 898
- IPO year
- 2019
- Website
- transmedics.com
Financial highlights
Full financialsIn fiscal 2025, TransMedics Group generated $605.5 million in revenue, up 37.1% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $190.3 million (+436.6% year over year), for a net margin of 31.4% versus a median of -38.8% in the prior 5 years. Gross margin was 59.9% (up from 59.4%) and operating margin 17.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $605.49M | $441.54M | $241.62M | $93.46M | $30.26M |
| Growth | +37.13% | +82.74% | +158.53% | +208.83% | +18.03% |
| Net income | $190.29M | $35.46M | $-25.03M | $-36.23M | $-44.22M |
| EPS (diluted) | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$105.45+23.70%
- Strong buy 3
- Buy 6
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.66 vs $0.27
- Surprise
- +144.44%
TMDX news
All TMDX news- Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire
- TransMedics: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Noteworthy Friday Option Activity: CCSI, TMDX, MSFTNasdaqCCSI, TMDX, MSFT
- TransMedics posts record intraday rally on “solid Q3 print”Seeking Alpha
- Healthcare Stocks Advance: OBX Surges 38%, ONCO Gains 32%, TMDX Rises 26%NasdaqBCTX, DAVI, OBX, ONCO
- Why is TransMedics stock surging today?Investing.com
- TransMedics Reports Third Quarter 2026 Financial ResultsNasdaq
- TransMedics (TMDX) Q3 2026 Earnings Call TranscriptNasdaq
TransMedics Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AXGNAxogen Inc. | 55.75 | -1.06% | $3.33B | vs TMDX |
| CNMDCONMED Corporation | 46.56 | +0.39% | $1.39B | vs TMDX |
| CBLLCeriBell Inc. | 27.39 | +6.37% | $1.06B | vs TMDX |
| LIVNLivaNova PLC | 90.73 | -1.46% | $5.00B | vs TMDX |
| INMDInMode Ltd. | 12.42 | -2.20% | $714.70M | vs TMDX |
| CVCapsoVision Inc. | 6.11 | -3.17% | $327.56M | vs TMDX |
| ELMDElectromed Inc. | 22.98 | -1.20% | $187.84M | vs TMDX |
| FOCLEDAP TMS S.A. ADR | 2.61 | -7.45% | $123.25M | vs TMDX |
Indexes, lists and sector
TransMedics Group stock FAQ
What is TransMedics Group's stock price today?
TMDX last traded at $85.25 as of Nov 20, 4:00 PM EST, down 9.33% on the day. Prices are delayed at least 15 minutes.
What is TMDX's P/E ratio?
TMDX trades at a trailing P/E ratio of 23.23 and a forward P/E of 34.31, compared with a median of 18.0 for its closest peers.
Who is TransMedics Group's CEO?
Dr. Waleed H. Hassanein M.D. is the chief executive officer of TransMedics Group Inc., which has about 898 employees.
What is the TMDX 52-week high?
The 52-week high for TMDX is $156.00 and the 52-week low is $60.11. The stock is currently 45.4% below its high.